BioNTech SE American Depositary Share - BNTX STOCK NEWS

BioNTech (Nasdaq: BNTX) announced the closing of its underwritten offering of 5,500,000 American Depositary Shares (ADSs) at $93.00 each, raising approximately $512 million. The underwriters have a 30-day option to purchase an additional 825,000 ADSs. BioNTech plans to utilize these funds to enhance its pipeline of immunotherapies targeting oncology and infectious diseases. J.P. Morgan, BofA Securities, and Berenberg led the offering. A registration statement regarding these securities was effective as of July 22, 2020.

BioNTech SE (BNTX) announced a firm commitment underwritten offering of 5,500,000 American Depositary Shares (ADSs) at a public price of $93.00 per ADS, generating gross proceeds of $511.5 million, increased from a previous offering of 5,000,000 ADSs. The offering closes on July 27, 2020. Simultaneously, a rights offering of up to 7,505,596 ordinary shares has been announced, with certain shareholders agreeing not to exercise their rights. The exercise period for ADS rights is from July 28 to August 14, 2020. Proceeds from the offering will not benefit the company.

The U.S. government has ordered 100 million doses of the BNT162 COVID-19 vaccine from Pfizer and BioNTech for $1.95 billion, with an option for an additional 500 million doses. This agreement supports the Operation Warp Speed initiative, aiming to deliver 300 million vaccine doses by 2021. The vaccine will be provided free to Americans. Pfizer and BioNTech plan to manufacture up to 100 million doses by year-end 2020 and potentially over 1.3 billion by the end of 2021. Clinical trials are underway, with the companies seeking regulatory review soon.

BioNTech SE (Nasdaq: BNTX) has announced a proposed public offering of 5 million American Depositary Shares (ADSs), with an existing shareholder granting underwriters an option for 750,000 additional ADSs. Following this, a rights offering for existing ADS and ordinary shareholders will occur, with a subscription price yet to be determined. Notably, shareholders controlling 74.83% of ordinary shares will not transfer or exercise their rights. Indications of interest from certain investors, including Pfizer, may total $200 million, though these are not binding commitments.

BioNTech (BNTX) and Pfizer announced preliminary findings from the German Phase 1/2 trial of their BNT162b1 mRNA COVID-19 vaccine. The study involved 60 participants and showed high SARS-CoV-2 neutralizing titers and robust CD4+ and CD8+ T cell responses. Notably, T cells exhibited a Th1 phenotype, suggesting strong antiviral potential. The vaccine also demonstrated broad neutralization against multiple variants, including the D614G strain. No serious adverse events occurred, with mild to moderate reactions reported. The data support further development, with plans for a larger global Phase 2b/3 trial anticipated to begin in late July 2020.

BioNTech (BNTX) and Pfizer announce an agreement with the UK to supply 30 million doses of their BNT162 mRNA-based COVID-19 vaccine, pending regulatory approval. The companies aim to manufacture up to 100 million doses by the end of 2020 and potentially over 1.3 billion doses by the end of 2021. The vaccine candidates are undergoing clinical trials and have shown potential for neutralizing antibodies at low doses. Both companies are engaged with multiple governments and the COVAX Facility for broader vaccine distribution.

Pfizer and BioNTech announced that two investigational COVID-19 vaccine candidates, BNT162b1 and BNT162b2, received Fast Track designation from the FDA. This designation aims to expedite the development of drugs addressing serious medical needs. Preliminary data from ongoing Phase 1/2 studies in the U.S. and Germany supported this designation. If successful, a Phase 2b/3 trial could begin soon, with potential for 100 million doses by end of 2020 and over 1.2 billion by end of 2021.

BioNTech (Nasdaq: BNTX) announced a conference call on July 1, 2020, at 11:00 a.m. EDT to discuss preliminary data from its ongoing Phase 1/2 trial of an mRNA-based vaccine against SARS-CoV-2. The firm continues to leverage its expertise in mRNA vaccine development and manufacturing to advance multiple vaccine candidates for infectious diseases and an extensive oncology pipeline. The call can be accessed via phone or webcast, with a replay available for 30 days post-event.

BioNTech (BNTX) and Pfizer announced preliminary results from a Phase 1/2 clinical trial of their mRNA vaccine candidate BNT162b1 against SARS-CoV-2. In 45 subjects, those receiving 10 µg and 30 µg doses exhibited significantly elevated RBD-binding IgG antibody levels and neutralizing antibody titers, outperforming convalescent sera. No serious adverse events were reported. If successful, a global Phase 2b/3 trial could start in July 2020, with plans to manufacture up to 100 million doses by the end of 2020 and over 1.2 billion by 2021, pending regulatory approval.